GDF-15 Protein Shows Promise as Cancer Biomarker Across Multiple Tumor Types

This study represents the most comprehensive analysis to date of Growth Differentiation Factor-15 (GDF-15) across multiple cancer types, revealing its potential as both a diagnostic biomarker and therapeutic target. GDF-15, a member of the TGF-β superfamily, has emerged as a critical regulator in tumor biology with the unique ability to interfere with immune responses.

Researchers analyzed GDF-15 expression patterns across 33 cancer types using multiple databases including TCGA, GTEx, and Human Protein Atlas. They found GDF-15 was significantly upregulated in 12 cancer types including breast, liver, lung adenocarcinoma, and thyroid cancers, while being downregulated in kidney and lung squamous cell carcinomas. The protein demonstrated high diagnostic accuracy in seven cancers, with area under the curve values exceeding 0.7.

The study revealed GDF-15's involvement in key cancer processes including tumor stemness, genomic instability, and immune evasion. Notably, GDF-15 expression correlated with immune cell infiltration patterns and immune checkpoint molecules, supporting its role as an "immune interferer" that may contribute to immunotherapy resistance. The protein also showed associations with RNA methylation modifications and cellular senescence pathways.

Validation studies using lung adenocarcinoma tissue microarrays confirmed that elevated GDF-15 protein levels significantly predicted poorer overall survival, translating the molecular findings into clinically relevant outcomes. This comprehensive characterization positions GDF-15 as a promising target for both diagnostic applications and therapeutic intervention, particularly in overcoming immunotherapy resistance.